Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment
European Journal of Clinical Pharmacology · 2026-07 · 82 (7)
DOI: 10.1007/s00228-026-04117-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 25.06.2026. Verfasst von Mohammed R Abdeldayem und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Kafrelsheikh University, Kafr El-Shaikh, 33511, Egypt. mohamed.med_2897@med.kfs.edu.eg. Hauptthemen laut MEDLINE: Triazoles, Pyridones, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Two-drug antiretroviral regimens are being investigated as alternatives to standard three-drug therapy for HIV-1. Doravirine/islatravir is a once-daily oral combination with promising efficacy and safety, but its overall clinical performance has not been systematically quantified. This study evaluated the efficacy and safety of doravirine/islatravir compared with standard triple option therapy in adults living with HIV-1. METHODS: PubMed, Scopus, Web of Science, and the Cochrane Library were systematically searched for phase III randomized controlled trials comparing doravirine/islatravir with standard triple option therapy. Eligible studies were independently screened, and data were extracted and pooled using R software. RESULTS: Six phase III trials involving 3,518 adults were included. At 48 weeks, doravirine/islatravir was associated with a significantly lower risk of virological failure (HIV-1 RNA ≥ 50 copies/mL) compared with standard triple option therapy (RR: 0.51, 95% CI [0.30-0.88]; P = 0.015). Rates of virological suppression (< 50 and < 200 copies/mL) were comparable between groups. No significant differences were observed in overall, serious, or grade 3-4 adverse events, or treatment discontinuation due to adverse events. Dose-stratified analyses showed that the 100/0.75 mg formulation was associated with significant declines in CD4 cell count and total lymphocyte count at 48 weeks, whereas the optimized 100/0.25 mg dose showed no significant immunological differences compared with standard triple option therapy. CONCLUSIONS: Doravirine/islatravir is an effective and generally well-tolerated two-drug regimen for HIV-1. The optimized 100/0.25 mg formulation maintained virological efficacy without significant short-term immunological differences versus standard triple option therapy; however, longer follow-up is needed to confirm its long-term immunological safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Kafrelsheikh University, Kafr El-Shaikh, 33511, Egypt. mohamed.med_2897@med.kfs.edu.eg.
- Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA. mohamed.med_2897@med.kfs.edu.eg.
- Faculty of Medicine, Kafrelsheikh University, Kafr El-Shaikh, 33511, Egypt.
- Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA.
- Faculty of Medicine, Yarmouk University, Irbid, Jordan.
Zitieren
APA
Abdeldayem, M. R., Elsherbeeny, A., & Beddor, A. (2026). Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment. European Journal of Clinical Pharmacology, 82(7). https://doi.org/10.1007/s00228-026-04117-4
Vancouver
Abdeldayem MR, Elsherbeeny A, Beddor A. Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment. European Journal of Clinical Pharmacology. 2026;82(7). doi:10.1007/s00228-026-04117-4
BibTeX
@article{Abdeldayem2026,
author = {Abdeldayem, Mohammed R and Elsherbeeny, Ahmed and Beddor, Ahmad},
title = {Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
volume = {82},
number = {7},
doi = {10.1007/s00228-026-04117-4}
}
EUVIMED